SelectScience
Join Free
Accelerating Science
NewsDrug discovery > Lead Discovery

New cannabinoid compound to treat irritable bowel syndrome

Oxford Cannabinoid Technologies

Oxford Cannabinoid Technologies has announced the pre-clinical development of a new cannabinoid compound ‘OCT461201’ to treat IBS

2 Apr 2020
Tom Casburn
Associate Editor

Industry news

Oxford Cannabinoid Technologies (OCT), a UK-based biotechnology firm researching the potential of cannabinoid-based medications for treating a range of acute and chronic conditions, has announced it has agreed a new licensing and business agreement with AskAt Inc. for a highly selective and potent CB2 agonist, OCT461201. The compound, which has been successfully evaluated in multiple disease models, is believed to be a potentially effective treatment for Irritable Bowel Syndrome (“IBS”) and other diseases.

OCT is now entering into pre-clinical development studies on the OCT461201 compound, including studies on drug metabolism and pharmacokinetics (DMPK), safety pharmacology and toxicology. The agreement includes the payment of undisclosed milestone and royalty payments.

“Medical cannabis and cannabinoid-based medicine is already proving to be an effective treatment for patients suffering from a range of incredibly distressing and debilitating medical conditions," said John Lucas, OCT’s Chief Commercial Officer. "The therapeutic promise of OCT461201 in treating IBS, and its potential to treat a further range of serious diseases and conditions, is an exciting opportunity for OCT and we look forward to advancing this compound through pre-clinical development and into clinical trials.”

OCT is set to make further announcements over the course of 2020 about the additional areas of research that it is prioritising, based on their clinical potential. These include cancer, immunology and neurology.

For more of the latest science news, straight to your inbox, become a member of SelectScience for free today>>

Links

Oxford Cannabinoid TechnologiesCompany website

Tags

Biopharmaceutical AdvancesBiopharmaceutical advances follow the development of pharmaceuticals derived from biotechnology, also known as biotechnology medicines. Biopharmaceuticals may be produced from cell lines, plants, or microbial cells. Important considerations of biopharmaceutical use include application, cost, production process and purification.Drug DeliveryDrug Delivery refers to dosage form, route of administration, formulations, technologies, and systems for transporting a pharmaceutical compound in the body as needed to safely achieve its desired therapeutic effect. Drug delivery is often approached via the biopharmaceutical or small molecule drug's formulation, but it may also involve medical devices or drug-device combination products. Considerations include instrumentation, software and services. Bioprocessing / FermentationBioprocessing is the use of biological materials to perform commercial, scientific or medical research processes. Biological materials used include cells, enzymes and organisms. Usually bioprocessing requires a batch or continuous bioreactor such as a fermentor or cell culture system. The advantages of using a reactor include high productivity, easy configuration, adjustable values and automation.Irritable Bowel SyndromeCannabinoidsCannabinoids are compounds found in cannabis that have therapeutic effects, such as pain relief, anti-inflammatory properties, and potential neuroprotective benefits. Research into cannabinoids is growing, particularly in the fields of pain management, neurological diseases, and cancer treatments. Browse our peer-reviewed product directory to find the best cannabinoid research tools, compare products, check reviews, and get pricing directly from manufacturers.Drug DevelopmentDrug development refers to the process of bringing a new drug to market.

Related articles

New cannabinoid compound to treat irritable bowel syndrome